Passing an ISO 14644-1 particle-count test is important—but it does not, by itself, prove that a sterile manufacturing environment is under control. Regulators increasingly expect manufacturers to demonstrate how cleanroom classification, HVAC performance, microbial monitoring, facility operations, investigations, and corrective actions work together as one contamination-control system. For quality assurance and compliance teams, the question is no longer simply:

“Did the cleanroom pass certification?”

The more important question is:

“Can we demonstrate that this facility remains in a state of control during actual operations?”

ISO classification is a snapshot—not the complete picture

ISO 14644-1 establishes a recognized method for classifying cleanrooms based on airborne particle concentrations. That classification provides an essential baseline, but it represents only one part of the contamination-control program.FDA guidance for sterile drug manufacturing states that clean-area control parameters should be supported by both microbiological and particle data. It also emphasizes qualification under dynamic conditions, routine monitoring, airflow-pattern evaluation, pressure control, documented alarms, and investigations when conditions deviate from established limits.In other words, a compliant particle count does not compensate for:

  • An unstable room-pressure cascade
  • Inadequate airflow around critical operations
  • Damaged or leaking HEPA filters
  • Unexplained microbial trends
  • Repeated HVAC alarms
  • Deferred maintenance
  • Poorly documented investigations
  • Corrective actions that were never verified for effectiveness

The FDA’s expectations are reflected in recent enforcement activity. In a 2025 warning letter, the agency cited inadequate airflow visualization, insufficient environmental-monitoring locations, poor trend evaluation, and the absence of a comprehensive assessment of contamination hazards. The FDA emphasized that an ongoing environmental-monitoring program is essential for detecting and responding to contamination risks.

FDA expectations and the Contamination Control Strategy

The formal term Contamination Control Strategy, or CCS, comes from EU GMP Annex 1—not directly from FDA regulations.EU Annex 1 requires manufacturers to implement a facility-wide CCS that identifies critical contamination-control points and evaluates the combined effectiveness of facility design, procedures, technical controls, monitoring, investigations, CAPA, and continuous improvement.Although the FDA does not require the same document by name, its aseptic-processing guidance and inspection findings follow a similar principle: contamination control must be supported by connected, scientifically justified evidence.For facilities operating in both U.S. and international markets, a well-developed CCS can therefore serve as the framework connecting:

  • Cleanroom classification and qualification
  • HVAC test and balance
  • Room-pressure relationships
  • HEPA-filter integrity testing
  • Airflow-visualization studies
  • Viable and nonviable environmental monitoring
  • Temperature and humidity control
  • Alarm and deviation management
  • Preventive maintenance
  • Root-cause investigations
  • Corrective and preventive actions
  • Periodic management review

Three questions an FDA investigator may ask about your HVAC system

1. Can you demonstrate that the intended airflow and pressure cascade are maintained during operations?An investigator may look beyond design values and ask for evidence that pressure relationships, airflow direction, air-change rates, and critical-zone protection remain effective during normal production.This evidence may include current test-and-balance data, continuous pressure records, alarm histories, airflow-visualization studies, room recovery testing, and documented responses to excursions.2. Do your HVAC, particle, and microbial data tell a consistent story?Each dataset may appear acceptable when reviewed separately. The real compliance risk often appears when the records are evaluated together.For example, a gradual decline in supply airflow may coincide with increasing particle counts, pressure instability, or microbial recoveries. If the facility reviews each report in isolation, the developing loss of control may be missed.Trend analysis should connect cleanroom certification results with environmental-monitoring data, HVAC performance, maintenance history, facility changes, and production events.3. What happens when performance begins to drift?Investigators will want to see more than an acceptable annual certification report. They may evaluate how the organization identifies adverse trends, establishes alert and action limits, investigates deviations, determines product impact, implements CAPA, and confirms that corrective actions were effective.Documentation should explain not only what failed, but also:

  • Why it happened
  • Whether other rooms, systems, or batches were affected
  • What immediate controls were implemented
  • What long-term corrective action was taken
  • How the organization verified that control was restored

Your certification report should support continuous proof of control

A defensible cleanroom program does not consist of isolated test reports stored until the next inspection. Certification and HVAC data should become part of the facility’s ongoing quality system.Micron Air & Mechanical Solutions helps sterile manufacturers build that evidence through:

  • Cleanroom certification
  • HVAC testing, adjusting, and balancing
  • HEPA-filter integrity testing
  • Room-pressure and airflow verification
  • Airflow-visualization support
  • Room recovery testing
  • Temperature and humidity mapping
  • Ongoing environmental-monitoring support
  • Historical performance and trend-data review

A well-executed air-balance report will not, by itself, guarantee a successful inspection. However, accurate HVAC documentation—connected to monitoring results, maintenance records, investigations, and CAPA—can provide critical evidence that the facility understands its risks and remains in control.Is your cleanroom data audit-ready?If your most recent certification report were reviewed alongside your microbial data, pressure alarms, maintenance records, and open CAPAs, would the information tell one consistent and defensible story?If the answer is unclear, it may be time to evaluate the gaps before an investigator does.Send Micron Air & Mechanical Solutions a message to schedule a free 15-minute contamination-control compliance check.Regulatory references: FDA Guidance for Industry—Sterile Drug Products Produced by Aseptic Processing, FDA 2025 Daewoo Pharmaceutical Warning Letter, and EU GMP Annex 1—Manufacture of Sterile Medicinal Products.